Doxorubicin cardiomyopathy. - <a href="../public/authorSummary-Chatterjee, Kanu.do">Kanu Chatterjee</a>, <a href="../public/authorSummary-Zhang, Jianqing.do">Jianqing Zhang</a>, <a href="../public/authorSummary-Honbo, Norman.do">Norman Honbo</a>, <a href="../public/authorSummary-Karliner, Joel S.do">Joel S Karliner</a>

Abstract	Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.
Authors	Kanu Chatterjee, Jianqing Zhang, Norman Honbo, Joel S Karliner
Journal	Cardiology (Cardiology) Vol. 115 Issue 2 Pg. 155-62 ( 2010) ISSN: 1421-9751 [Electronic] Switzerland
PMID	20016174 (Publication Type: Journal Article, Review)
Chemical References	Antibiotics, Antineoplastic Doxorubicin
Topics	Antibiotics, Antineoplastic (adverse effects) Cardiomyopathies (chemically induced, diagnosis, pathology, therapy) Doxorubicin (adverse effects) Humans Myocardium (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!